Perspective Therapeutics, Inc.

CATX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-6.2M $-4.7M $-3.7M $-6.0M $-3.9M $-3.5M $-2.8M
Depreciation & Amortization $68.0K $471.0K $576.0K $685.4K $739.1K $847.1K $888.6K
Depreciation $68.0K $471.0K $576.4K $685.4K $739.1K $847.1K —
Amortization $45.0K $107.0K $37.0K $18.5K $19.6K $15.7K —
Stock-Based Compensation $372.0K $290.0K $205.0K $186.0K $108.4K $173.3K $242.7K
Net Cash from Operating Activities $-5.7M $-3.9M $-3.5M $-3.2M $-3.1M $-2.4M $-2.4M
Investing Activities
Capital Expenditures $549.0K $479.0K $133.0K $19.0K $6.6K $55.1K $137.5K
Business Acquisitions — — — — — — —
Net Cash from Investing Activities $1.5M $8.8M — — $-12.8K $-95.5K $-157.9K
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $-9.0K $39.0K — — $3.3M $3.1M $3.0M
Net Change in Cash $-4.2M $4.9M $-2.5M $4.8M $227.2K $560.5K $433.4K
Free Cash Flow $-6.3M $-4.4M $-3.7M $-3.2M $-3.1M $-2.5M $-2.6M
← Newer Page 2 of 2 Older →